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Abstract Idiopathic midline destructive disease is a rare
disease, characterized by a progressive ulceration and
destruction of midline facial structures. We report a case
with localization on the palate for which she received radio-
therapy. Later she developed a second localization on the
posterior pharyngeal wall for which she was re-irradiated,
without severe sequels. Twice a complete regression was
observed.
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Introduction
Idiopathic midline destructive disease is a rare, which is
characterized by a progressive ulceration and destruc-
tion of midline facial structures, including the nasal
cavity, the paranasal sinuses and the palate. In most
cases, radiotherapy is an eVective treatment [1]. We
describe a woman with twice a localization of idiopathic
midline destructive disease, which were both treated
with irradiation.
Case report
A woman, 46 years of age, was referred with complaints of
nasal discharge while drinking. She was otherwise healthy
and there was no history of substance use. Physical exami-
nation revealed an almost complete destruction of the mem-
branous nasal septum and perforations of the soft and hard
palate of 3 and 5 mm, respectively. Further examination of
the head and neck region and general examination showed
no abnormalities. Computed tomography showed extensive
destruction of the hard palate. Biopsy showed a non-spe-
ciWc inXammation and Wbrosis (Fig. 1). There were no signs
of Wegener’s granulomatosis, malignant lymphoma, tuber-
culosis or Epstein-Barr virus infection. Serum tests showed
negative results for anti-neutrophil cytoplasmic antibodies
(ANCA) and syphilis. A diagnosis of idiopathic midline
destructive disease was made.
The patient was then treated with radiation therapy to a
total dose of 52 Gy in 26 fractions. At the end of the radia-
tion course, a grade 1 mucositis and grade 1 erythema were
observed. A complete regression of the disease occurred.
After 4 years, the defect in the palate was closed surgically
using a temporalis muscle Xap.
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lowing complaints. On examination, a tumor-like lesion
with a central ulcer was seen on the posterior pharyngeal
wall. A CT-scan of the head and neck region showed a soft
tissue mass on the posterior pharyngeal wall with extension
from the level of the soft palate and nasopharynx to the
level of the epiglottis. Biopsy showed the same histologic
appearance as previously. The site of the original lesion
was without any signs of abnormalities.
It was decided to treat this new localization with re-irra-
diation. During treatment, the patient experienced grade 1
erythema and grade 2 mucositis. She experienced swallow-
ing complaints for 4 months. Complete regression occurred
again.
Four years after re-irradiation the patient presented again
with progressive swallowing complaints and nasal speech.
On physical examination, an ulcer was seen on the poster-
ior pharyngeal wall with a diameter of 1-cm, which had a
diVerent clinical appearance than the former two lesions.
Therefore, the diVerential diagnosis included a radiation-
induced ulcer or recurrence midline destructive disease.
Biopsy was not taken because it was most likely that patho-
logical examination of this lesion could not distinguish
between these two entities and because of an increased
probability of wound-healing problems after biopsy in a
highly irradiated area. We decided to treat this lesion as a
radiation ulcer and the patient was proposed to undergo
hyperbaric oxygen therapy, which she refused. Therefore,
as an alternative, we decided to treat her with pentoxyWlline
and high dose vitamin E, which she has used for one year.
In the subsequent 12 months, the ulcer as well as her com-
plaints gradually decreased.
During the last follow-up visit (more than 5 years after
re-irradiation), there were no signs of recurrent tumor or
other severe radiation sequels, while a small ulcer still
persists. Besides a mild xerostomia, she had no other com-
plaints.
Discussion
Idiopathic midline destructive disease (IMDD), also known
as lethal midline granuloma (LMG), is a rare disease which
is clinically characterized by a progressive, unrelenting
ulceration and necrosis of the nasal cavity or the midline
facial structures. This disorder has to be distinguished from
other progressive, ulcerative disorders of the midline facial
tissues, including cocaine use, sarcoidosis, infections like
tuberculosis and syphilis, various neoplasms like vestibular
or septal carcinoma, Wegener’s granulomatosis, and poly-
morphic reticulosis (PMR) [2]. In contrast to all the other
diseases, which have distinct histopathological features that
distinguish them from IMDD, the histopathological Wnd-
ings of IMDD are nonspeciWc. It is essentially a diagnosis
per exclusionem.
Some authors believe that IMDD is an early phase of
PMR [2]. Others state that all cases referred to as IMDD or
PMR are in fact nasal T-cell (natural killer cell) lymphomas
(NTL) [1, 3], with a possible association with the Epstein-
Barr virus [4]. However, Barker and Hosni recently
reported a case of IMDD in which no other cause could be
diagnosed by current techniques and they proposed that
IMDD remains a valid description in a small number of
cases [5]. In our case the clinical course (with only local-
ized disease) and histology (no atypia or Epstein-Barr virus
in the tumor) argue strongly against lymphoma and for
IMDD.
Untreated IMDD is eventually fatal. No more than
approximately 100 cases have been reported, of which only
part is characterized as IMDD and the other cases as PMR
Fig. 1 Histological picture of 
idiopathic midline destructive 
disease detail (40£ objective, 
Hematoxilin & Eosin stain) 
showing predominantly small 
irregular lymphocytes admixed 
with histiocytes and some 
granulocytes. The lymphoid 
cells do not appear obviously 
malignant. Low power view of 
biopsy (5£ objective, 
Hematoxilin & Eosin stain) 
show an ulcerative surface (left) 
and the inWltrate (right) with 
prominent vessels with swollen 
endothelial cells123
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and local control, are diYcult to interpret. The preferred
treatment of IMDD is radiation therapy to a dose of at least
50 Gy [1, 3]. A 5-year overall survival after radiation ther-
apy has been reported from 15 to 75%. Local control varies
between 63 and 77% [1–4]. Cases reported as NTL do
worse compared to IMDD [1]. Some authors administer
chemotherapy in case of NTL, although no diVerence in
survival in patients with or without the addition of chemo-
therapy could be established [3].
In our case, a total dose of 52 Gy in 26 fractions was
used which is generally considered to be suYcient. The
margins taken during the Wrst treatment were adequate
according to the clinical tumor extension. Also because of
the long time-interval, the second lesion can be considered
to be a new localization of the disease.
It was decided to treat this new localization with re-irra-
diation for the following reasons. The largest part of the
new localization was outside the initial treatment Weld
implying that only part of the previously irradiated area
would be treated again with the second course of radiother-
apy. Second, the interval between the initial course of
radiotherapy and relapse was more than 8 years and the
total dose administered was 52 Gy, which may imply that a
substantial amount of initial radiation damage to the normal
tissues could have recovered [6–8].
Data on re-treatment of IMDD after local failure are
scarce. Both Chen et al. [1] and Sakata et al. [3] mention a
case with local relapse with successful re-irradiation without
giving any detailed information. One patient with a local
relapse of IMDD beneWted from salvage chemotherapy [3],
whereas two other patients, who were diagnosed as NTL,
failed on a combination of re-irradiation and chemotherapy
[1]; also on these patients no detailed information regarding
radiotherapy was provided.
In conclusion, radiation therapy is the treatment of
choice for idiopathic midline destructive disease. In case of
a second localization in the irradiated area re-irradiation
should be considered.
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